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Envelope (env) proteins of certain endogenous retroviruses (ERVs) participate in various pathophysiological processes. In this
study, we characterized pathophysiologic properties of two murine leukemia virus-type ERV (MuLV-ERV) env genes cloned from
the ovary of C57BL/6J mice. The two env genes (named ENVOV1 and ENVOV2), with 1,926 bp coding region, originated from two
MuLV-ERV loci on chromosomes 8 and 18, respectively. ENVOV1 and ENVOV2 were ∼75 kDa and predominantly expressed on
the cell membrane. They were capable of producing pseudotype murine leukemia virus virions. Tropism trait and infectivity of
ENVOV2 were similar to the polytropic env; however, ENVOV1 had very low level of infectivity. Overexpression of ENVOV2, but
not ENVOV1, exerted cytotoxic effects and induced expression of COX-2, IL-1β, IL-6, and iNOS. These findings suggest that the
ENVOV1 and ENVOV2 are capable of serving as an env protein for virion assembly, and they exert differential cytotoxicity and
modulation of inflammatory mediators.
1. Introduction
Ancient infection of germline cells with exogenous retro-
viruses established a genome-wide random embedment
of proviruses, called endogenous retroviruses (ERVs), and
Mendelian genetics governs their inheritance to the off-
springs [1]. ERVs are reported to exist in the genome
of all vertebrates and constitute approximately 8% of the
human genome and 10% of the mouse genome [2–4].
The majority of ERVs identified so far are reported to
be defective primarily based on their inability to encode
intact polypeptides for gag (group specific antigen), pol
(reverse transcriptase), and env (envelope) genes, which are
essential for the retroviral life cycle [5]. However, recent
studies identified a number of ERVs, which retain intact
coding potentials for gag, pol, and/or env genes, and some
of them are reported to be associated with a range of
normal physiology (e.g., placental morphogenesis) as well as
pathogenic processes (e.g., multiple sclerosis, schizophrenia,
injury, and chronic fatigue syndrome) [6–10]. On the other
hand, biology of porcine ERVs (PERVs) has been studied
extensively because of the potential transmission of PERVs to
humans as an adverse side effect of xenotransplantation [11].
The env glycoproteins of certain human ERVs (HERVs)
have been implicated in diverse disease processes [12–16].
For instance, the env glycoproteins of HERV-K, HERV-E,
and ERV-3 were characterized as tumor-associated antigens
in different types of cancer [15–18]. The HERV-W env
glycoprotein, called syncytin-1, is highly expressed in glial
cells within central nervous system of multiple sclerosis, an
autoimmune disease, patients [13]. It is proposed that potent
proinflammatory properties of syncytin-1 contribute to neu-
ronal inflammation and resultant damage to oligodendro-
cytes during the progression of multiple sclerosis [12]. On
the other hand, syncytin-1 and HERV-FRD env glycoprotein,
called syncytin-2, are reported to play an essential role during
embryonic development by controlling formation of pla-
cental syncytiotrophoblasts primarily through their highly
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fusogenic properties [19–22]. Additional env glycoproteins
have been identified and characterized from murine ERVs
(syncytin-A and syncytin-B) and endogenous Jaagsiekte
sheep retrovirus (enJSRV), and their roles in placenta
morphogenesis are similar to syncytin-1 and syncytin-2 [7,
23, 24]. The findings from recent studies provide evidence
suggesting that env glycoproteins of certain ERVs play a
critical role in biological processes of normal physiology as
well as diseases.
During a survey of expression profile of MuLV-ERV
subgenomic env transcripts in various normal tissues of
C57BL/6J mice, two putative full-length env transcripts
were identified in the ovary. In this study, the biological
characteristics of these two MuLV-ERV env genes, named
ENVOV1 and ENVOV2, were investigated by examining a
selective set of pathophysiologic parameters.
2. Materials and Methods
2.1. Animals. Female C57BL/6J mice (approximately 12
weeks old) were purchased from the Jackson Laboratory
(Bar Harbor, Me) and housed according to the guidelines
of the National Institutes of Health. The Animal Use and
Care Administrative Advisory Committee of the University
of California, Davis, approved the experimental protocol.
Three mice were sacrificed by cervical dislocation for tissue
collection without any pretreatment, and tissue samples were
snap-frozen.
2.2. RT-PCR Analyses. RNA isolation and cDNA synthesis
were performed primarily according to the relevant protocols
provided by the kit manufacturer. Briefly, total RNAs were
extracted using an RNeasy kit (Qiagen, Valencia, Calif) and
cDNAs were synthesized using 100 ng of total RNA from
each sample (tissue or cell) and the Sensiscript reverse
transcriptase (Qiagen). The primers capable of amplifying
the full length as well as subgenomic MuLV-ERV transcripts
were designed based on the MAIDS (murine acquired
immunodeficiency virus) virus-related provirus (GenBank
No. S80082) [25]: forward, 5′-CAT TTG GAG GTC CCA
CCG AGA-3′ (MV1K) and reverse, 5′-CTC AGT CTG TCG
GAG GAC TG-3′ (MV2D). The following are the primer
sets used for inflammatory mediators: COX-2 (forward, 5′-
ACA CAG TGC ACT ACA TCC TGA C-3′ and reverse, 5′-
ATC ATC TCT ACC TGA GTG TC-3′), ICAM-1 (forward,
5′-AGC TGT TTG AGC TGA GCG AGA-3′ and reverse, 5′-
CTG TCG AAC TCC TCA GTC A-3′), IL-1β (forward, 5′-
GAC AGT GAT GAG AAT GACCTG-3′ and reverse, 5′-GAA
CTC TGC AGA CTC AAA CTC CA-3′), IL-6 (forward, 5′-
GCC TTC CCT ACT TCA CAA GTC CG-3′ and reverse, 5′-
CAC TAG GTT TGC CGA GTA GAT CTC-3′) [26], iNOS
(forward, 5′-ACA AGC TGC ATG TGA CAT CGA-3′ and
reverse, 5′-CAG AGC CTG AAG TCA TGT TTG C-3′), and
TNF-α (forward, 5′-GCA TGA TCC GCG ACG TGG AA-3′
and reverse, 5′-AGA TCC ATG CCG TTG GCC AG-3′) [27].
In addition, β-actin (forward, 5′-CCA ACT GGG ACG ACA
TGG AG-3′ and reverse, 5′-GTA GAT GGG CAC AGT GTG
GG-3′) was used as an internal expression control [28]. The
density of amplified products (applied only for inflammatory
mediators) was measured using KODAK Molecular Imaging
Software ver. 4.5 (Carestream Health, Rochester, NY), and it
was normalized to β-actin control.
2.3. Cloning and Sequencing of env Transcripts. The RT-
PCR products of the MuLV-ERV subgenomic transcripts
(∼2.9 Kb) were cloned into the pGEM-T Easy vector
(Promega, Madison, Wis) followed by plasmid DNA prepa-
ration using a kit from Qiagen, and sequencing analysis at
Davis Sequencing Inc (Davis, Calif) or Molecular Cloning
Laboratory (South San Francisco, Calif). DNA sequences
were analyzed using Vector NTI-ver. 10 (Invitrogen, Carls-
bad, Calif) or Editseq and MegAlign program within DNAS-
TAR ver. 8.0.2 (DNASTAR,Madison, Wis).
2.4. Construction of ENVOV1 and ENVOV2 Expression Vec-
tors. The coding regions of the ENVOV1 and ENVOV2 were
amplified by PCR from their respective original cDNA clones
using a set of primers embeddedwith restriction enzyme sites
for cloning into the pcDNA4/HisMax (Invitrogen): forward
with NotI, 5′-CGC GGC GGC CGC ATG GAA GGT CCA
GCG TTC TC-3′, ENVOV1-reverse with XhoI, 5′-GGC TCG
AGT TAT TCA CGT GAT TCC ACT TTT TCT GG-3′, and
ENVOV2-reverse with XhoI, 5′-GGC TCG AGT TAT TCA
CGT GAT TCC ACT TCT TCT GG-3′. The amplified coding
sequences after 10 PCR cycles were cloned into the pGEMT-
Easy vector (Promega) followed by digestion with NotI
and XhoI and subsequently cloned into pcDNA4/HisMax
(Invitrogen).
2.5. Cell Lines. The GP2-293 packaging cells (purchased
from Clontech, Mountain View, Calif), tsA201 cells (a
derivative of HEK293 cells), COS-7 cells, and COS-1 cells
were maintained in Dulbecco’s modified eagle medium
(DMEM, Invitrogen) supplemented with 10% fetal bovine
serum, streptomycin, and penicillin G. Five other cell lines
(HeLa, Neuro-2a, MDCK, HCT 116, and NIH3T3) were
cultured according to the protocols recommended by the
American Type Culture Collection (Manassas, Va).
2.6. Assays for Production, Tropism, and Infectivity of Pseu-
dotype LacZ-MuLV Virions. The GP2-293 cells, which were
seeded onto a 6-well plate at a concentration of 5 × 105
cells per well, were cotransfected with pQCLIN (Clon-
tech, Mountain View, Calif) and pcDNA4/HisMax-ENVOV1
or pcDNA4/HisMax-ENVOV2 plasmid using Lipofectamine
2000 (Invitrogen). The following env proteins were used for
tropism and infectivity controls: ecotropic (pEco), 4070A
amphotropic (pAmpho), 10A1 amphotropic (p10A1) with
a broader host range than 4070A, and G glycoprotein of
the vesicular stomatitis virus (VSV-G) (Clontech). Culture
supernatants containing pseudotype viral particles were
passed through a 0.45 μM filter (Fisher Scientific, Pittsburgh,
Pa). Transfection efficiency was estimated by counting the
stained cells under the microscope after X-gal staining.
For each cell line (a total of 8 cell lines) employed
for tropism and infection analysis, 5 × 104 cells/well were
seeded onto a 24-well plate and incubated overnight in
preparation of viral transduction. Subsequently, the medium
Mediators of Inflammation 3
was replaced with 0.5mL of serial dilutions of culture
supernatants containing pseudotype LacZ-MuLV virions,
in which Polybrene (Sigma, Milwaukee, Wis) was added
(8 μg/mL), followed by washing after 4 hours and incubation
with 0.5mL of fresh media for 2 days. The infected cells
were treated with fixing solution (2% formaldehyde and
0.2% glutaraldehyde in PBS) and stained with X-gal solution.
Cells stained blue were counted under the microscope as an
infection unit.
2.7. Western Blot Analyses. To confirm expression of the
pcDNA4/HisMax-ENVOV1 or pcDNA4/HisMax-ENVOV2 con-
struct, Western blot analysis was performed following trans-
fection into tsA201 cells using Fugene 6 reagent (Roche,
Mannheim, Germany). At 2 days after transfection, the cells
were harvested, and Western blot analysis was performed.
Briefly, the membrane, blocked in 5% nonfat dry milk
(NFDM), was incubated with a goat antibody specific for
gp69/71 of Rauscher MuLV (1 : 2000 dilution with 5%
NFDM in TBST [Tris-buffered saline with Tween 20])
obtained from ViroMed Biosafety Laboratories (Camden,
NJ) followed by an anti-goat-HRP antibody (1 : 5000, Santa
Cruz Biotechnology, Santa Cruz, Calif). The protein sig-
nal was visualized using ECL reagents (GE healthcare,
Pittsburgh, Pa). A similar protocol was used to detect
env glycoprotein from supernatants of the GP2-293 cells
producing pseudotype LacZ-MuLV virions.
2.8. Immunocytochemistry. HeLa cells, which were trans-
fected with the pcDNA4/HisMax-ENVOV1 or pcDNA4/
HisMax-ENVOV2 construct, were harvested and transferred
into 0.1% poly-L-Lysine coated coverslips and incubated for
1 day. Cells were then immunostained with a goat antibody
specific for gp69/71 (1 : 200 diluted in culture medium,
ViroMed Biosafety Laboratories) and fixed with both 4%
paraformaldehyde. Fixed cells were incubated with a Texas-
Red-conjugated antigoat IgG secondary antibody (1 : 200
diluted in PBS, Vector Laboratories, Burlingame, Calif) and
stained cells were visualized by a Zeiss microscope using
AxioVison software version 4.5 (Carl Zeiss, Jena, Germany).
2.9. Cytotoxicity and Cell Proliferation Assays. HeLa cells,
which were transfected with the pcDNA4/HisMax-ENVOV1
or pcDNA4/HisMax-ENVOV2 construct, were subjected to
cytotoxicity assay using a Cytotoxicity Detection Kit (Roche,
South San Francisco, Calif) according to the protocol
recommended by the manufacturer. Absorbance was mea-
sured at 490 nm with a reference at 600 nm using a
reader from Molecular Devices (Sunnyvale, Calif). Cell
proliferation rate was measured from these cells using
the colorimetric MTT (3- (4, 5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide) (Sigma, Milwaukee, Wis)
assay as described previously [29]. Absorbance was read
at 560 nm with a reference at 600 nm using a reader
(MolecularDevices). All experiments were performed at least
in triplicate, and 4 independent experiments were repeated.
2.10. Analysis of Inflammatory Mediators. RAW264.7 cells,
which were transfected with the pcDNA4/HisMax-ENVOV1
or pcDNA4/HisMax-ENVOV2 construct, were harvested at
1 day after transfection, and they were examined for
expression of a set of inflammatory mediators at mRNA
levels by RT-PCR, and the relevant protocols and reagents
are described in Section 2.2 above.
2.11. Statistical Analysis. Statistical analysis was performed
using two-tailed Student’s t-test and statistical significance
was determined as ∗P < .05 and ∗∗P < .01.
3. Results
3.1. Identification and Initial Characterization of Two MuLV-
ERV env Subgenomic Transcripts Expressed in the Ovary
of C57BL/6J Mice. The expression profiles of MuLV-ERV
env genes in various normal tissues (liver, lung, salivary
gland, adrenal gland, brain, skin, ovary, and uterus) of
C57BL/6J mice were investigated. A number of putative
subgenomic transcripts with varying sizes, ranging from
∼1Kb to ∼5Kb, which may be generated by splicing and/or
deletion, were differentially expressed in each tissue. Among
them were ∼2.9Kb bands presumed to be amplified from
full-length MuLV-ERV env transcripts, and their expression
was evident in the ovary and uterus as well as other tissues
(Figure 1(a)). Sequencing analysis revealed that the two
2,892 bp transcripts were env mRNAs, which were generated
by a single splicing using the well-characterized donor and
acceptor signals [30]. A subsequent open reading frame
analysis revealed that the two full-length MuLV-ERV env
genes, named ENVOV1 and ENVOV2, retain intact coding
potential for env glycoproteins of 641 amino acids. While the
nucleotide and polypeptide sequences of the ENVOV2 was
identical to an env gene of an polytropic murine leukemia
virus (MuLV)-related retroviral sequence from NFS/N mice,
the ENVOV1 has not been reported yet [31].
Prior to the functional characterization of the ENVOV1
and ENVOV2, they were aligned with four different refer-
ence env polypeptides displaying different host tropisms:
ecotropic, xenotropic, polytropic, and modified polytropic
(Figure 1(b)). It turned out that both ENVOV1 and ENVOV2
had a higher level of sequence similarity to the polytropic/
modified polytropic env polypeptides compared to the
others. Both the ENVOV1 and ENVOV2 share the identical
sequence in the variable region A and proline rich region,
while one amino acid residue was different in the variable
region B and R peptide, respectively. To identify the putative
MuLV-ERVs encoding the ENVOV1 and ENVOV2, respec-
tively, the C57BL/6J genome sequence (Build 37.1) from
the National Center for Biotechnology Information (NCBI)
was surveyed with the respective env nucleotide sequences
using the BLAST program [32]. The putative proviruses
presumed to encode the ENVOV1 and ENVOV2 were mapped
to ideogram data of chromosome 8 and ideogram data of
chromosome 18, respectively. Both MuLV-ERVs retained the
coding potential for env polypeptide, and ENVOV2 also had
the coding potential for pol polypeptide (Figure 1(c)).
To examine whether the ENVOV1 and ENVOV2 are
able to produce full-length env polypeptides, they were
overexpressed in a human cell line followed by Western blot
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Figure 1: Identification of full-length env transcripts from the ovary of C57BL/6J mice. (a) A number of MuLV-ERV subgenomic transcripts
were expressed in normal tissues (liver, lung, salivary gland, adrenal gland, brain, and skin) of C57BL/6J mice. A schematic diagram indicates
the locations of primers used for amplification of the subgenomic transcripts. (b) The amino acid sequences of two intact env genes,
named ENVOV1 and ENVOV2, which were isolated from the ovary (indicated with an arrow in panel (a)), were compared to reference
env polypeptides with known tropism traits (GeneBank accession number: AAG39911 (Eco), ACY30460 (Xeno), AAO37283 (Poly), and
AAA88318 (m.Poly)). (c) The putative MuLV-ERV proviruses harboring the ENVOV1 and ENVOV2 genes were mapped to chromosomes 8
and 18 of C57BL/6J genome, respectively. SU (surface domain), TM (transmembrane domain), VRA (variable region A), VRB (variable
region B), PRR (proline rich region), LTR (long terminal repeat), R (repeat), and U (unique region).
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Figure 2: Coding potential and membrane localization of ENVOV1 and ENVOV2 polypeptides. (a) The coding potential of the ENVOV1 and
ENVOV2 polypeptides was confirmed by overexpression followed byWestern blot analysis using antibody against RauscherMuLV gp69/71 env
polypeptide. (b) The cellular distribution of the overexpressed ENVOV1 and ENVOV2 polypeptides was examined by immunocytochemistry
using antibody against Rauscher MuLV gp69/71 polypeptide, and their membrane staining pattern was evident. The cells transfected with a
blank plasmid serves as a negative control (mock). DAPI (4′,6-diamidino-2-phenylindole).
detection using an anti-gp69/71 (env) antibody. A protein
band of ∼75 kDa, which was about the size of MuLV-
ERV env polypeptides, was detected (Figure 2(a)). Moreover,
the subcellular distribution of these env polypeptides was
examined by transient transfection followed by immunocy-
tochemistry using the same antibody used for the Western
blot analysis. Both the ENVOV1 and ENVOV2 proteins were
evidently expressed on the cell membrane as was expected
from the retroviral env polypeptides (Figure 2(b)).
3.2. Infectivity and Tropism Traits of ENVOV1 and ENVOV2
Polypeptides. Two relevant characteristics, tropism and
infectivity, of the ENVOV1 and ENVOV2 polypeptides were
determined using a retroviral packaging system and com-
pared to reference env proteins with known host tropisms:
ecotropic, amphotropic, and pantropic. Prior to the analyses
of infectivity and tropism traits, the packaging potential
of the ENVOV1 and ENVOV2 polypeptides and release of
pseudotype LacZ-MuLV virions were confirmed by detection
of ∼75 kDa bands in the culture supernatants collected after
transfection (Figure 3). Interestingly, a markedly higher level
of env protein was detected in the supernatants presumed
to contain ENVOV2-packaged pseudotype virions compared
to the ENVOV1 samples. This finding may suggest that the
ENVOV2 polypeptide is more efficiently produced and/or
packaged during the course of virion assembly compared
to the ENVOV1. The infectivity and tropism traits of the
ENVOV1 and ENVOV2 polypeptides were then examined
by infection of various cell types derived from human,
nonhuman primate, mouse, and dog. It revealed that
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Figure 3: Production of pseudotype LacZ-MuLV virions. Pres-
ence of the pseudotype LacZ-MuLV virus particles in culture
supernatants of the GP2-293 packaging cells was confirmed by
detection of the env polypeptides using antibody against Rauscher
MuLV gp69/71. Arrow indicates the env polypeptides. Supernatants
collected from cells transfected with a blank plasmid serves as a
negative control (mock).
the pseudotype LacZ-MuLV virions packaged with either
ENVOV1 or ENVOV2 were capable of infecting both mouse as
well as nonmouse cells suggesting their polytropic tropism
trait, which is consistent with the alignment data presented
in Figure 1 (Table 1). While the pseudotype ENVOV2-LacZ-
MuLV virions demonstrated infectivity that is very similar to
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Figure 4: Cytopathic effects of the ENVOV1 and ENVOV2 polypeptides. (a) and (b) Cytotoxic property of the ENVOV2 polypeptide, but not
ENVOV1 polypeptide, was observed during cytotoxicity assay bymeasurement of lactate dehydrogenase release andmorphologic examination
of cells (200x magnification). The degree of cytotoxicity was normalized to the no DNA (Panel (a)). (c) ENVOV2 polypeptide’s inhibitory
effect on cell proliferation was demonstrated by MTT assay, which measures cell viability, following overexpression. All experiments were
performed in triplicate. ∗ and ∗∗ indicate statistical significance (∗P < .05; ∗∗P < .01).
the amphotropic and pantropic controls, the ENVOV1-LacZ-
MuLV virions had substantially low infection titers compared
to the controls, probably due to low expression level and/or
inefficient packaging potential during virion assembly.
3.3. Cytopathic Characteristics of ENVOV1 and ENVOV2
Polypeptides. In this experiment, the cytopathic effects of
the ENVOV1 and ENVOV2 polypeptides were examined by
overexpression followed by measurement of cytotoxicity
and inhibition of cell proliferation. Cytotoxic property of
the ENVOV2 polypeptide was clearly demonstrated by both
colorimetric quantitative assay and microscopic examina-
tion of morphological characteristics, including adherence
to culture plate (Figures 4(a) and 4(b)). In contrast,
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Table 1: Tropism trait and infectivity of the ENVOV1 and ENVOV2 polypeptides. Infection titer unit (U/mL): number of LacZ positive cells
per mL of supernatant containing virus particles. ND: not detectable.
Cell lines
Infection titer (U/mL)
ENVOV1 ENVOV2 pEco pAmpho p10A1 pVSVG
Human
HeLa 1.6 × 101 1.5 × 104 ND 2.2 × 104 2.2 × 104 4.7 × 104
tsA201 3.1 × 101 2.0 × 106 ND 2.8 × 106 1.4 × 106 8 × 106
HCT116 2.0 × 101 3.2 × 104 ND 2.7 × 104 4.0 × 104 1.7 × 104
Nonhuman primate
COS-1 4.0 × 101 2.0 × 105 ND 2.0 × 105 3.8 × 105 1.2 × 105
COS-7 6.9 × 101 8.4 × 105 ND 1.3 × 106 3.2 × 106 5.2 × 106
Mouse
NIH3T3 2.0 × 101 9.5 × 104 4.5 × 105 1.7 × 104 3.3 × 104 1.4 × 104
Neuro2a ND 2.1 × 104 4.4 × 103 2.7 × 103 2.1 × 103 4.8 × 103
Dog
MDCK ND 3.2 × 101 ND 3.2 × 102 2.6 × 102 1.2 × 102
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Figure 5: Effects of ENVOV1 and ENVOV2 polypeptides on expression of inflammatory mediators. (a) and (b) The effects of the ENVOV1 or
ENVOV2 polypeptide in RAW264.7 on the expression of various inflammatory mediators are presented. Differential modulation potentials
for inflammatory mediators were observed between ENVOV1 and ENVOV2 polypeptides. The densitometric value of each inflammatory
mediator was normalized to β-actin, and a graph was formulated. Three different forms of negative control were included in this experiment:
no DNA, pcDNA4 (blank pcDNA4/HisMax plasmid), and GR11 (similar insert size as ENVOV1 and ENVOV2: mouse glucocorticoid receptor
in pcDNA4/HisMax). The assay was performed in triplicate. ∗ and ∗∗ indicate statistical significance (∗P < .05; ∗∗P < .01).
no significant cytotoxic effects were observed in the cells
overexpressed with the ENVOV1 polypeptide compared to
negative controls. On the other hand, the overexpression
of the ENVOV2 polypeptide, but not ENVOV1 polypeptide,
evidently inhibited cell proliferation, which was measured
by colorimetric quantitation of cell growth (Figure 4(c)). It
is likely that inhibition of cell proliferation by the ENVOV2
polypeptide is linked to its cytotoxic effect, and it is unclear
how its high infection titer correlates with the cytopathic
characteristics.
3.4. Modulation of Inflammatory Mediators by ENVOV1 and
ENVOV2 Polypeptides. To investigate whether the ENVOV1
and ENVOV2 play a role in inflammation, changes in
mRNA expression of a set of inflammatory mediators
were surveyed following their overexpression in RAW264.7
alveolar macrophage cells. The set include proinflammatory
mediators of COX-2 (cyclooxygenase-2), ICAM-1 (inter-
cellular adhesion molecule 1), iNOS (inducible nitric oxide
synthase), IL-1β, IL-6, and TNF-α. The expression of
four proinflammatory mediators, COX-2, iNOS, IL-1β,
and IL-6, was significantly increased by overexpression of
ENVOV2 polypeptide but not ENVOV1 (Figures 5(a) and
5(b)). In contrast, no significant changes in ICAM-1 and
TNF-α levels were detected following the overexpression
of either the ENVOV1 or the ENVOV2 polypeptide. The
findings from this study suggest that the ENVOV1 and
ENVOV2 polypeptides differentially participate in certain
signaling events controlling the production of inflammatory
mediators.
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4. Discussion
Two MuLV-ERV env genes with intact coding potential,
named ENVOV1 and ENVOV2, were isolated from the ovary of
normal C57BL/6J mice and their biological properties were
characterized. Although the sequence of one (ENVOV2) of
the two env genes has been reported previously, its biological
functions have not been characterized [31]. The findings
from this study suggest that both the ENVOV1 and ENVOV2
polypeptides, which were determined to confer polytropic
tropism, participate in a range of biological processes,
such as retroviral packaging, cell death, proliferation, and
inflammation.
The results from this study suggest that putative MuLV-
ERVs, or unidentified exogenous retroviruses, which are
packaged with either ENVOV1 or ENVOV2 polypeptide, are
capable of infecting cells of mice as well as other species,
such as humans, nonhuman primates, and dogs. De novo
as well as stress-related activation of the MuLV-ERVs, which
are packaged with these env polypeptides, may be followed
by infection of specific cells of local as well as distant. In
addition to the potential cytopathic effects examined in
this study, the genomic random integration of the proviral
DNAsmay be directly linked to various pathogenic outcomes
following infection. Further in vivo studies are needed to
determine infectivity of the MuLV-ERVs packaged with these
env polypeptides in mice as well as other species.
ERVs have been associated with a range of diseases,
such as sepsis, multiple sclerosis, and injury whose central
pathology includes inflammatory conditions [12, 33–37].
Some reports provided evidence that certain ERV env gene
products, but not the relevant virus particles, play a role in
the inflammatory processes associated with various patho-
logic phenotypes [38, 39]. The HERV-W syncytin-1 exerted
its inflammatory effects by induction of proinflammatory
mediators, such as IL-1β, IL-6, IL-12, iNOS, and TNF-
α, leading to neuron inflammation in multiple sclerosis
patients [12, 40]. The findings from this study that the
ENVOV2 polypeptide is capable of modulating inflammatory
mediators suggest its potential roles in immunologic home-
ostasis as well as in various diseases involving inflammatory
conditions, such as sepsis [41, 42].
A markedly higher level of packaging and subsequent
release of pseudotype LacZ-MuLV virions was predicted
with the ENVOV2 compared to the ENVOV1, based on
the detection of abundant env polypeptide in the culture
supernatants of ENVOV2 samples. It is consistent with
the finding that the ENVOV2-packaged virions (pseudotype
ENVOV2-LacZ-MuLVs) had higher infection titers compared
to the ENVOV1-packaged virions (pseudotype ENVOV1-
LacZ-MuLVs). It is possible that the putative high packaging
rate with the ENVOV2 polypeptide is directly linked to its
efficient transcription and/or translation as well as stability.
On the other hand, abundant presence of the ENVOV2
polypeptide in the cytoplasmmay explain, at least in part, the
characteristics of cytotoxicity and inhibition of proliferation
compared to the ENVOV1. Throughout the entire coding
sequences, nine amino acid residues (V22I, R24G, R158G,
Q161R, R362G, G518R, G528R, D608, and K640E) were
different between the ENVOV1 and ENVOV2 polypeptides.
Further investigation may be needed to learn the roles of
these polymorphic residues in stability as well as pathogenic
characteristics, including infectivity, of the ENVOV1 and
ENVOV2 polypeptides.
5. Conclusions
The findings from this study indicate that certain MuLV-ERV
env polypeptides, such as ENVOV2, may participate in a range
of pathophysiologic processes as an envelope of MuLV-ERV
virions and/or independently.
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